MATRIXYL
Solid evidence for a cosmetic peptide, though most data comes from company-sponsored studies rather than independent research. The single human trial showed measurable improvements in skin texture and wrinkle depth.
Primarily studied by cosmetic chemists and dermatological researchers investigating topical anti-aging treatments.
Since Feb 2026
7 total, 1 human
What is MATRIXYL?
This synthetic peptide emerged from French cosmetic research in the 1990s as one of the first commercially successful anti-aging compounds. Found in premium skincare products from brands like Olay and L'Oréal, it represents the intersection of peptide science and mainstream cosmetics. The compound spawned several variations, including Matrixyl 3000 and Synthe'6, each targeting different aspects of skin aging.
The peptide works by tricking skin cells into thinking collagen has been damaged and needs repair. When applied topically, it binds to receptors on fibroblasts—the cells responsible for maintaining skin structure—and triggers a cascade of rebuilding activity. Think of it as sending a false alarm that prompts your skin to ramp up production of the proteins that keep it firm and elastic.
What the Research Shows
Seven studies total with only one human clinical trial, though that study was well-designed and showed statistically significant results over 12 weeks.
Notable Studies
Röper B, Kaisig D, Auer F et al. · Strahlenther Onkol (2004)
RCT · Phase 2 · n=205 · 0 Gy radiotherapy course
Adak A, Castelletto V, Hamley IW et al. · ACS Appl Mater Interfaces (2024)
Animal · 20 days
Zeng Q, Jiang J, Wang J et al. · Mar Drugs (2019)
Animal
Paccola AGL, Santos TMCD, Minelo MC et al. · Molecules (2025)
In Vitro72 hours
Gomes A, Bessa LJ, Fernandes I et al. · Microbiol Spectr (2022)
In Vitro
Reported Benefits
Regulatory Status
Last verified: Feb 2026
Related Peptides
This information is for research purposes only and does not constitute medical advice. Always consult a licensed physician before using any peptides.